MedTrace Logo

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

NCT00635245 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-11

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as CP-751871, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase I trial is studying the side effects and best way to give CP-751871 in treating patients with early-stage breast cancer that can be removed by surgery.

Conditions

Interventions

BIOLOGICAL

figitumumab

OTHER

imaging biomarker analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

conventional surgery

PROCEDURE

magnetic resonance spectroscopic imaging

PROCEDURE

neoadjuvant therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Douglas Yee, MD · Masonic Cancer Center, University of Minnesota

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00635245 on ClinicalTrials.gov